RSV Monoclonal Antibody for Infants Sets Sales Records

While monoclonal antibody (mAbs) treatments for infants have been available for many years, the recently approved version has become widely accepted.

Sanofi today announced its third-quarter earnings report, which included sales of its newly approved mAbs. This innovative product delivers long-term passive immunization to protect infants from respiratory syncytial virus (RSV)- related lower respiratory tract infections.

Beyfortus™ sales in the third quarter far exceeded Wall Street analyst projections.

After a second external filling line was licensed, additional capacity enabled increased supply in collaboration with AstraZeneca, which is responsible for manufacturing.

The company stated in a press release that sales were €645 million ($696m), driven by early deliveries in the U.S. and rollout in several countries, including Canada, France, Germany, Spain, Portugal, Belgium, and Ireland.

Sanofi confirmed that Beyfortus is available for the 2024-2025 RSV season in about 20 countries. In the United States, Beyfortus has become generally available.

The U.S. FDA-approved Beyfortus in 2023.

In October 2024, The Lancet published a study estimating Beyfortus's effectiveness against RSV-associated hospitalizations for bronchiolitis at 73%.